Application of a Novel UPLC-MS/MS Method for Analysis of Rivaroxaban Concentrations in Dried Blood Spot and Plasma Samples Collected from Patients with Venous Thrombosis
Molecules · 31.08.2024 · 29 (17) · 4140
DOI: 10.3390/molecules29174140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 31.08.2024. Verfasst von Kornel Pawlak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Pharmacy & Pharmacokinetics, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland. Hauptthemen laut MEDLINE: Rivaroxaban, Tandem Mass Spectrometry, Dried Blood Spot Testing, Venous Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Poznan University of Medical Sciences, Poznan University of Medical Sciences Doctoral School.
Abstract (Originalsprache)
Despite a higher safety profile compared to vitamin K antagonists, rivaroxaban therapy is still connected with multiple adverse effects, such as a high risk of bleeding. Thus, therapeutic drug monitoring (TDM) of rivaroxaban concentrations is suggested. An alternative to plasma samples can be dried blood spots (DBS), which minimize the cost of sample storage and transport. In this study, we developed a UPLC-MS/MS method for the analysis of rivaroxaban in DBS and plasma samples. Chromatographic separation was achieved on a Zorbax Eclipse Plus C18 column (2.1 × 100 mm; 3.5 µm, Agilent Technologies Inc., Santa Clara, CA, USA) with a mobile phase consisting of water and acetonitrile, both containing 0.1% formic acid. The analytes were detected using a positive ionization mode by multiple reaction monitoring. We validated the method according to ICH guidelines. The precision and accuracy were satisfactory. Extraction recovery was approximately 57% and 66% for DBS and plasma samples, respectively. A high correlation between rivaroxaban concentrations in plasma and DBS samples collected from patients was confirmed with Deming regression. The suitability of both sampling techniques for the rivaroxaban TDM was also verified by Bland–Altman plots based on DBS-predicted and observed plasma concentrations. In addition, we found a significant relationship between rivaroxaban concentrations and coagulation parameters, including prothrombin time (PT) and international normalized ratio (INR).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physical Pharmacy & Pharmacokinetics, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland.
- Doctoral School, Poznan University of Medical Sciences, 60-812 Poznan, Poland.
- Department of Vascular & Endovascular Surgery, Angiology and Phlebology, Poznan University of Medical Sciences, Dluga St 1/2., 61-848 Poznan, Poland.
ORCID-Profile: Kornel Pawlak, Łukasz Kruszyna, Marta Karaźniewicz-Łada
Förderung
- Poznan University of Medical Sciences
- Poznan University of Medical Sciences Doctoral School
Zitieren
APA
Pawlak, K., Kruszyna, Ł., Miecznikowska, M., & Karaźniewicz-Łada, M. (2024). Application of a Novel UPLC-MS/MS Method for Analysis of Rivaroxaban Concentrations in Dried Blood Spot and Plasma Samples Collected from Patients with Venous Thrombosis. Molecules, 29(17), 4140. https://doi.org/10.3390/molecules29174140
Vancouver
Pawlak K, Kruszyna Ł, Miecznikowska M, Karaźniewicz-Łada M. Application of a Novel UPLC-MS/MS Method for Analysis of Rivaroxaban Concentrations in Dried Blood Spot and Plasma Samples Collected from Patients with Venous Thrombosis. Molecules. 2024;29(17):4140. doi:10.3390/molecules29174140
BibTeX
@article{Pawlak2024,
author = {Pawlak, Kornel and Kruszyna, Łukasz and Miecznikowska, Marta and Karaźniewicz-Łada, Marta},
title = {Application of a Novel UPLC-MS/MS Method for Analysis of Rivaroxaban Concentrations in Dried Blood Spot and Plasma Samples Collected from Patients with Venous Thrombosis},
journal = {Molecules},
year = {2024},
volume = {29},
number = {17},
pages = {4140},
doi = {10.3390/molecules29174140}
}
EUVIMED